Targeting Epigenetics in Cancer

被引：183

作者：

Bennett, Richard L. ^{[1
]}

Licht, Jonathan D. ^{[1
]}

机构：

[1] Univ Florida, Dept Med, Hlth Canc Ctr, Div Hematol & Oncol, Gainesville, FL 32606 USA

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58 | 2018年 / 58卷

关键词：

epigenetics; DNA methylation; histone acetylation; histone methylation; epigenetic readers; anticancer therapies; HISTONE DEACETYLASE INHIBITOR; ACUTE MYELOID-LEUKEMIA; GENOME-WIDE ANALYSIS; PHASE-I; DNA METHYLATION; OPEN-LABEL; SOMATIC MUTATIONS; CHEMICAL PROBE; HDAC INHIBITOR; INACTIVATING MUTATIONS;

D O I：

10.1146/annurev-pharmtox-010716-105106

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Alterations of genes regulating epigenetic processes are frequently found as cancer drivers and may cause widespread alterations of DNA methylation, histone modification patterns, or chromatin structure that disrupt normal patterns of gene expression. Because of the inherent reversibility of epigenetic changes, inhibitors targeting these processes are promising anticancer strategies. Small molecules targeting epigenetic regulators have been developed recently, and clinical trials of these agents are under way for hematologic malignancies and solid tumors. In this review, we describe how the writers, readers, and erasers of epigenetic marks are dysregulated in cancer and summarize the development of therapies targeting these mechanisms.

引用

页码：187 / 207

页数：21

共 159 条

[1] IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours [J].

Amary, M. Fernanda ;

Bacsi, Krisztian ;

Maggiani, Francesca ;

Damato, Stephen ;

Halai, Dina ;

Berisha, Fitim ;

Pollock, Robin ;

O'Donnell, Paul ;

Grigoriadis, Anita ;

Diss, Tim ;

Eskandarpour, Malihe ;

Presneau, Nadege ;

Hogendoorn, Pancras C. W. ;

Futreal, Andrew ;

Tirabosco, Roberto ;

Flanagan, Adrienne M. .

JOURNAL OF PATHOLOGY, 2011, 224 (03) :334-343

[2]

[Anonymous], 2014, DISCRETE DYN NAT SOC, DOI DOI 10.1155/2014/934369

[3] Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer [J].

Asangani, Irfan A. ;

Dommeti, Vijaya L. ;

Wang, Xiaoju ;

Malik, Rohit ;

Cieslik, Marcin ;

Yang, Rendong ;

Escara-Wilke, June ;

Wilder-Romans, Kari ;

Dhanireddy, Sudheer ;

Engelke, Carl ;

Iyer, Mathew K. ;

Jing, Xiaojun ;

Wu, Yi-Mi ;

Cao, Xuhong ;

Qin, Zhaohui S. ;

Wang, Shaomeng ;

Feng, Felix Y. ;

Chinnaiyan, Arul M. .

NATURE, 2014, 510 (7504) :278-+

[4] Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma [J].

Assouline, Sarit E. ;

Nielsen, Torsten Holm ;

Yu, Stephen ;

Alcaide, Miguel ;

Chong, Lauren ;

MacDonald, David ;

Tosikyan, Axel ;

Kukreti, Vishal ;

Kezouh, Abbas ;

Petrogiannis-Haliotis, Tina ;

Albuquerque, Marco ;

Fornika, Daniel ;

Alamouti, Sepideh ;

Froment, Remi ;

Greenwood, Celia M. T. ;

Oros, Kathleen Klein ;

Camglioglu, Errol ;

Sharma, Ayushi ;

Christodoulopoulos, Rosa ;

Rousseau, Caroline ;

Johnson, Nathalie ;

Crump, Michael ;

Morin, Ryan D. ;

Mann, Koren K. .

BLOOD, 2016, 128 (02) :185-194

[5] A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors [J].

Banerji, Udai ;

van Doorn, Leni ;

Papadatos-Pastos, Dionysis ;

Kristeleit, Rebecca ;

Debnam, Phillip ;

Tall, Matthew ;

Stewart, Adam ;

Raynaud, Florence ;

Garrett, Michelle Dawn ;

Toal, Martin ;

Hooftman, Leon ;

De Bono, Johann Sebastian ;

Verweij, Jaap ;

Eskens, Ferry A. L. M. .

CLINICAL CANCER RESEARCH, 2012, 18 (09) :2687-2694

[6] An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma [J].

Baratta, Maria Giuseppina ;

Schinzel, Anna C. ;

Zwang, Yaara ;

Bandopadhayay, Pratiti ;

Bowman-Colin, Christian ;

Kutt, Jennifer ;

Curtis, Jennifer ;

Piao, Huiying ;

Wong, Laura C. ;

Kung, Andrew L. ;

Beroukhim, Rameen ;

Bradner, James E. ;

Drapkin, Ronny ;

Hahn, William C. ;

Liu, Joyce F. ;

Livingston, David M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (01) :232-237

[7] High-resolution profiling of histone methylations in the human genome [J].

Barski, Artern ;

Cuddapah, Suresh ;

Cui, Kairong ;

Roh, Tae-Young ;

Schones, Dustin E. ;

Wang, Zhibin ;

Wei, Gang ;

Chepelev, Iouri ;

Zhao, Keji .

CELL, 2007, 129 (04) :823-837

[8] MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L [J].

Bernt, Kathrin M. ;

Zhu, Nan ;

Sinha, Amit U. ;

Vempati, Sridhar ;

Faber, Joerg ;

Krivtsov, Andrei V. ;

Feng, Zhaohui ;

Punt, Natalie ;

Daigle, Amanda ;

Bullinger, Lars ;

Pollock, Roy M. ;

Richon, Victoria M. ;

Kung, Andrew L. ;

Armstrong, Scott A. .

CANCER CELL, 2011, 20 (01) :66-78

[9] Phase I trial of valproic acid and lenalidomide in patients with advanced cancer [J].

Bilen, Mehmet Asim ;

Fu, Siqing ;

Falchook, Gerald S. ;

Ng, Chaan S. ;

Wheler, Jennifer J. ;

Abdelrahim, Maen ;

Erguvan-Dogan, Basak ;

Hong, David S. ;

Tsimberidou, Apostolia M. ;

Kurzrock, Razelle ;

Naing, Aung .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) :869-874

[10] The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling [J].

Bitoun, Emmanuelle ;

Oliver, Peter L. ;

Davies, Kay E. .

HUMAN MOLECULAR GENETICS, 2007, 16 (01) :92-106

← 1 2 3 4 5 6 7 8 9 10 →